If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  NCI Says Chemotherapy Plus Radiation Improves Cervical Cancer Survival WASHINGTON, DC -- Feb. 22, 1999 -- The National Cancer Institute (NCI) today mailed a clinical announcement to thousands of physicians stating that strong consideration should be given to adding chemotherapy to radiation therapy in the treatment of invasive cervical cancer. The mailing alerts physicians who treat cancer to the findings of five different studies -- all large, randomised clinical trials -- showing that women in the studies benefited from the use of radiation therapy and chemotherapy given together. Up to now, surgery or radiation therapy alone has been considered the standard treatment for cervical cancer that has spread locally (within the cervix) or regionally (within the pelvis). "The findings of these five trials are remarkably consistent," said NCI director Richard Klausner, M.D. "They are likely to change the standard of care for invasive cervical cancer." Three of the studies cited in NCI's clinical announcement will appear in the New England Journal of Medicine. Because of their potential implications for public health, the articles about these studies were released today, in advance of their publication date. The remaining two studies will be published later in 1999. Several hundred women were enrolled in each of the five trials, which were carried out by NCI's Clinical Trials Cooperative Groups in centres around the country. Their cancers varied from disease confined to the cervix to disease that had spread from the cervix to other pelvic tissues. In three of the studies, women were randomly divided into groups that received either radiation alone or radiation plus concomitant chemotherapy. The chemotherapy agents used were cisplatin and 5-fluorouracil, also known as 5-FU (two studies) and cisplatin alone (one study). In all three trials, the proportion of women alive after about three years of follow-up was higher in the groups receiving chemotherapy plus radiation than in those receiving only radiation therapy. In the two other studies, all patients received concomitant chemotherapy and radiation. However, the chemotherapy drugs differed between the arms. In one arm of each of these trials, the chemotherapy used was hydroxyurea while in the other arms, the chemotherapy included cisplatin. In both trials, the groups who received cisplatin had better survival rates. NCI's clinical announcement states that, although the best chemotherapy regimen for cervical cancer has not been determined, significant results were seen using cisplatin alone or cisplatin in combination with 5-FU and other agents.
|
